免疫吸附实现非人灵长类rAAV5肝脏基因重复递送
该研究在非人灵长类中探索免疫吸附(IA)清除抗AAV5中和抗体后重复肝靶向基因递送的可行性。首次给予rAAV5-hSEAP后7周,全部动物再次给予rAAV5-hFIX;半数动物在二次暴露前接受IA。未IA者未检出hFIX,而IA组全部动物hFIX达治疗水平,并确定了兼容成功重复给药的抗AAV5 NAB阈值。
要点
- IA可降低抗AAV5中和抗体,使rAAV5肝脏重复递送成功。
- 未IA时重复给予rAAV5-hFIX未检出hFIX表达。
- IA组全部动物hFIX表达达治疗水平。
核心结论
- 临床上可用的IA操作可在相关动物模型中实现rAAV5基因转移的成功重复给药。
- 人受试者IA后抗AAV NAB水平分析确认该操作降低抗AAV NAB的安全性和有效性。
研究设计与样本
- 非人灵长类研究:动物静脉给予rAAV5-hSEAP,7周后全部再次给予rAAV5-hFIX。
- 半数接受rAAV5-hSEAP的动物在第二次rAAV5暴露前接受IA。
- 通过检测hSEAP和hFIX蛋白水平评估转导效力。
主要发现
- 未先IA而重复给予rAAV5-hFIX后未检出hFIX。
- 接受IA的全部动物显示治疗水平的hFIX表达。
- 研究展示了与成功重复给药兼容的抗AAV5 NAB水平阈值。
关键数值与推荐
- 首次rAAV5处理后7周进行第二次rAAV5给药。
- 以hSEAP和hFIX蛋白水平评估rAAV5转导效力。
- 以免疫球蛋白G检测作为临床转化的替代评估。
临床怎么用
- 对存在抗AAV中和抗体的患者,IA可能为AAV肝脏基因重复递送提供可行策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adeno-associated virus (AAV)-based liver gene therapy has been shown to be clinically successful. However, the presence of circulating neutralizing antibodies (NABs) against AAV vector capsids remains a major challenge as it may prevent successful transduction of the target cells. Therefore, there is a need to develop strategies that would enable AAV-mediated gene delivery to patients with preexisting anti-AAV NABs. In the current study, the feasibility of using an immunoadsorption (IA) procedure for repeated, liver-targeted gene delivery in nonhuman primates was explored. The animals were administered IV with recombinant AAV5 (rAAV5) carrying the reporter gene human secreted embryonic alkaline phosphatase (hSEAP). Seven weeks after the first rAAV treatment, all of the animals were readministered with rAAV5 carrying the therapeutic hemophilia B gene human factor IX (hFIX). Half of the animals administered with rAAV5-hSEAP underwent IA prior to the second rAAV5 exposure. The transduction efficacies of rAAV5-hSEAP and rAAV5-hFIX were assessed by measuring the levels of hSEAP and hFIX proteins. Although no hFIX was detected after rAAV5-hFIX readministration without prior IA, all animals submitted to IA showed therapeutic levels of hFIX expression, and a threshold of anti-AAV5 NAB levels compatible with successful readministration was demonstrated. In summary, our data demonstrate that the use of a clinically applicable IA procedure enables successful readministration of an rAAV5-based gene transfer in a clinically relevant animal model. Finally, the analysis of anti-AAV NAB levels in human subjects submitted to IA confirmed the safety and efficacy of the procedure to reduce anti-AAV NABs. Furthermore, clinical translation was assessed using an immunoglobulin G assay as surrogate.
引用
- Salas D, Kwikkers KL, Zabaleta N, et al. Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv. 2019. PMID: 31501158. doi:10.1182/bloodadvances.2019000380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。